Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia
European Journal of Endocrinology · 10.01.2023 · 188 (1) · 109-117
DOI: 10.1093/ejendo/lvac006 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Endocrinology, online erschienen am 19.01.2023. Verfasst von Lea Tschaidse und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Hydrocortisone, Adrenal Hyperplasia, Congenital. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, German Research Foundation, NIH HHS.
Abstract (Originalsprache)
Objective
Poorly controlled salt-wasting (SW) congenital adrenal hyperplasia (CAH) patients often require high 9α-fluorocortisol doses as they show high levels of 17-hydroxyprogesterone (17OHP), which is a mineralocorticoid (MC)-receptor antagonist.
Design
We investigated the renin–angiotensin–aldosterone system in patients with SW-CAH receiving twice daily modified-release hydrocortisone (MR-HC, Efmody) compared with standard glucocorticoid (GC) therapy.
Methods
Data were analyzed from the 6-month, phase 3 study of MR-HC (n = 42) versus standard GC therapy (n = 41). MC replacement therapy remained unchanged throughout the study. Blood pressure, serum potassium, serum sodium, plasma renin activity (PRA), and serum 17OHP and androstenedione concentrations were analyzed at baseline, 4, 12, and 24 weeks.
Results
The median serum 17OHP in the morning was significantly lower on MR-HC compared with standard GC at 24 weeks (2.5 nmol L–1 (IQR 8.3) versus 10.5 nmol L–1 (IQR 55.2), P = .001). PRA decreased significantly from baseline to 24 weeks in patients on MR-HC (0.83 ng L–1 s–1 (IQR 1.0) to 0.48 ng L–1 s–1 (IQR 0.61), P = .012) but not in patients on standard GC (0.53 ng L–1 s–1 (IQR 0.66) to 0.52 ng L–1 s–1 (IQR 0.78), P = .613). Serum sodium concentrations increased from baseline to 24 weeks in patients on MR-HC (138.8 ± 1.9 mmol L–1 to 139.3 ± 1.8 mmol L–1, P = .047), but remained unchanged on standard GC (139.8 ± 1.6 mmol L–1 to 139.3 ± 1.9 mmol L–1, P = .135). No significant changes were seen in systolic and diastolic blood pressure and serum potassium levels.
Conclusion
6 months of MR-HC therapy decreased PRA and increased sodium levels indicating a greater agonist action of the 9α-fluorocortisol dose, which may be due to the decreased levels of the MC-receptor antagonist 17OHP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.
- Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, United Kingdom.
- Hospices Civils de Lyon, Fédération d'Endocrinologie, Groupement hospitalier Est, Bron Cedex, France.
- Department of Women's and Children's Health, Karolinska Institutet and Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.
- Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Nicole Reisch, Wiebke Arlt, Anders Juul, Ashwini Mallappa, Alessandro Prete, Philippe A Touraine, Marcus Quinkler
Förderung
- Deutsche Forschungsgemeinschaft
- German Research Foundation
- NIH HHS
- National Institutes of Health
Zitieren
APA
Tschaidse, L., Reisch, N., Arlt, W., Brac de la Perriere, A., Linden Hirschberg, A., Juul, A., Mallappa, A., Merke, D. P., Newell-Price, J. D. C., Perry, C. G., Prete, A., Rees, D. A., Stikkelbroeck, N. M. M. L., Touraine, P. A., Coope, H., Porter, J., Ross, R. J. M., & Quinkler, M. (2023). Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia. European Journal of Endocrinology, 188(1), 109-117. https://doi.org/10.1093/ejendo/lvac006
Vancouver
Tschaidse L, Reisch N, Arlt W, Brac de la Perriere A, Linden Hirschberg A, Juul A, et al. Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia. European Journal of Endocrinology. 2023;188(1):109-117. doi:10.1093/ejendo/lvac006
BibTeX
@article{Tschaidse2023,
author = {Tschaidse, Lea and Reisch, Nicole and Arlt, Wiebke and Brac de la Perriere, Aude and Linden Hirschberg, Angelica and Juul, Anders and Mallappa, Ashwini and Merke, Deborah P and Newell-Price, John D C and Perry, Colin G and Prete, Alessandro and Rees, D Aled and Stikkelbroeck, Nike M M L and Touraine, Philippe A and Coope, Helen and Porter, John and Ross, Richard John M and Quinkler, Marcus},
title = {Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia},
journal = {European Journal of Endocrinology},
year = {2023},
volume = {188},
number = {1},
pages = {109--117},
doi = {10.1093/ejendo/lvac006}
}
EUVIMED